Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.30 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27049672 | 1.00 | GAA (0.33) | GAAL3MBTL1PTGESALOX5PGR | |
| SCHEMBL27049673 | 1.00 | GAA (0.33) | GAAL3MBTL1PTGESALOX5PGR | |
| SCHEMBL27049671 | 0.99 | GAA (0.32) | GAAL3MBTL1PTGESALOX5PGR | |
| SCHEMBL27049670 | 0.96 | GAA (0.31) | GAAL3MBTL1 | |
| SCHEMBL26355796 | 0.95 | PTGES (0.33) | GAAL3MBTL1PTGESALOX5PGR | |
| SCHEMBL24152041 | 0.90 | GAA (0.31) | GAAL3MBTL1 | |
| SCHEMBL24907983 | 0.90 | GAA (0.31) | GAAL3MBTL1 | |
| SCHEMBL24047368 | 0.90 | GAA (0.31) | GAAL3MBTL1 | |
| SCHEMBL26367434 | 0.88 | ALOX5 (0.35) | GAAL3MBTL1ALOX5PLA2G2APLA2G4A | |
| SCHEMBL27049680 | 0.88 | ALOX5 (0.35) | GAAL3MBTL1ALOX5PLA2G2APLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025872-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-20240025872-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025872-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, CYP1B1, CYP1A1 | GAA 1869/4885L3MBTL1 933/4885PTGES 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.